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Abstract 
Betulinic acid (BA) and its derivatives possess potent pharmacological activity against cancer and 
HIV. As with many phytochemicals, access to BA is limited by the requirement for laborious extraction 
from plant biomass where it is found in low amounts. This might be alleviated by metabolically 
engineering production of BA into an industrially relevant microbe such as Saccharomyces cerevisiae 
(yeast), which requires complete elucidation of the corresponding biosynthetic pathway. However, while 
cytochrome P450 enzymes (CYPs) that can oxidize lupeol into BA have been previously identified from 
the CYP716A subfamily, these generally do not seem to be specific to such biosynthesis and, in any case, 
have not been shown to enable high-yielding metabolic engineering. Here RoCYP01 (CYP716A155) 
was identified from the BA-producing plant Rosmarinus officinalis (rosemary), and demonstrated to 
effectively convert lupeol into BA, with strong correlation of its expression and BA accumulation. This 
was further utilized to construct a yeast strain that yields > 1 g/L of BA, providing a viable route for 
biotechnological production of this valuable triterpenoid. 
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Introduction 
 
Betulinic acid (BA) and its derivatives have attracted great attention all over the world due to their 
promising pharmaceutical potential, especially anticancer and anti-HIV activity. In 1995, it was found 
that BA seems to serve as a melanoma-specific antitumor agent (Pisha et al. 1995). Indeed, BA is still 
considered as one of most promising natural products for developing new anticancer drugs, and 
numerous studies in the past ten years have been aimed at elucidating the efficacy and mechanism of BA 
and its derivatives in inhibiting cancer cell growth (Chintharlapalli et al. 2007; Liu et al. 2012; Mertens-
Talcott et al. 2013; Majeed et al. 2014; Pal et al. 2015; Ye et al. 2017). Moreover, many BA derivatives 
possess potent inhibitory activity against HIV. 3-O-(3,3-Dimethylsuccinyl)betulinic acid (bevirimat, 
also known as PA-457) is capable of potently inhibiting replication of both wild type and drug-resistant 
HIV-1 isolates by blocking conversion of the capsid precursor p25 to mature capsid protein p24 (Li et al. 
2003), with success completion of phase I and IIa clinical trials reported in 2009 (Qian et al. 2010). 
Recently, many new BA derivatives have been synthesized and found to exhibit inhibitory activity against 
bevirimat-resistant HIV-1 variants (Dang et al. 2013; Zhao et al. 2016). 
All the BA derivatives mentioned above, including bevirimat, are produced by semi-synthesis from 
BA. Unfortunately, the content of BA in the commercially used bark from birch (genus Betula) is quite 
low, 0.025% by weight, although this is alleviated to some degree by the alcoholic precursor betulin, 
which is found in higher amounts and can be converted to BA (Pezzuto and Kim 1998). Much effort has 
gone into increasing yields from phytochemical isolation of BA and betulin (Krasutsky et al. 2003; 
Siddiqui and Aeri 2016; Šiman et al. 2016), as well as conversion of betulin to BA (Pezzuto and Kim 
1998; Csuk et al. 2006; Tulisalo et al. 2013; Ressmann et al. 2017). However, all these methods are based 
on isolation of BA and/or betulin from plant materials, which consumes large amounts of plant biomass, 
and requires a tedious and laborious extraction and purification process that is environmental unfriendly.  
Synthetic biology approaches have recently succeeded in producing many important plant-derived 
natural products at industrial scales, such as artemisinic acid (Paddon et al. 2013) and resveratrol (Li et 
al. 2015). This requires complete characterization of genes involved in the biosynthesis of the target 
natural products. BA is produced by oxidation of C-28 in lupeol, which is derived from the common 
triterpenoid precursor 2,3-oxidosqualene via a polycyclization and rearrangement reaction catalyzed by 
lupeol synthase (Dewick 2002; Thimmappa et al. 2014). This oxidative conversion of C-28 from a methyl 
to carboxylic acid is catalyzed by cytochrome P450 enzymes (CYPs), specifically members of the 
CYP716A subfamily (Thimmappa et al. 2014; Ghosh 2017). Although it has been reported that 
CYP716A12 (Fukushima et al. 2011; Carelli et al. 2011), CYP716A15 (Fukushima et al. 2011), 
CYP716AL1 (Huang et al. 2012), CYP716A179 (Tamura et al. 2017), CYP716A80 (Khakimov et al. 
2015) and CYP716A81 (Khakimov et al. 2015) are capable of catalyzing the conversion of lupeol to BA, 
these react more efficiently with - and -amyrin rather than lupeol. Recently, CYP716A180 was cloned 
from B. platyphylla and reported to selectively react with lupeol relative to - and -amyrin (Zhou et al. 
2016). However, this has not yet led to construction of a high-yielding microbial strain suitable for 
biotechnological production of BA. Rosemary (Rosmarinus officinalis) has been reported to produce BA 
(Razboršek et al. 2007), and RNA-seq data for this has recently become available (Boachon et al. 2018), 
which can accessed from the corresponding website (http://medicinalplantgenomics.msu.edu). Here this 
resource was used to identify RoCYP01 (CYP716A155), which was found to preferentially react with 
lupeol to afford BA. This further enabled construction of an efficient BA biosynthetic pathway in yeast, 
with additional engineering leading to a strain that produces > 1 g/L.  
 
Materials and Methods 
 
Materials  
 
Standard chemicals including betulinic acid (J&K Scientific, Ltd), betulin (J&K Scientific, Ltd), lupeol 
(Nanjing SenBeiJia Biological Technology Co., Ltd.), ursolic acid (Shanghai ZZbio Co., Ltd), oleanolic 
acid (Shanghai ZZbio Co., Ltd), α-amyrin (Shanghai ZZbio Co., Ltd) and β-amyrin (HePeng Biotech 
Co., Ltd.) were used. Amino acids were supplied from Sigma. Genes were amplified using Phanta Super-
Fidelity DNA polymerase (Vazyme Biotech Co., Ltd) and Taq polymerase (TransGEN Biotech Co., 
Ltd). DNA gel purification and plasmid extraction kits were purchased from TIANGEN Biotech Co., 
Ltd. Restriction enzymes and T4-DNA polymerase from Thermo Fisher Scientific Co., Ltd., as well as 
pEASY-Blunt Cloning kit from TransGen Biotech Co., Ltd, were used for DNA cloning. The optimized 
gene sequences of RoCYP01 and AtLUP were synthesized by Synbio Technologies. 
S. cerevisiae strains BY4741 (ATCC 201388) and CEN.PK2-1D (EUROSCARF 30000B) were used 
as the hosts for functional elucidation and biosynthetic pathway assembly, respectively. E. coli DH5α 
was used for gene cloning. NZY medium was used for cultivation of E. coli. SD or SG media lack of 
corresponding nutrients (e.g. uracil, histidine, methionine, leucine or any combinations of them) were 
used for strain selection and fermentation of yeasts. 
 
Identification and amplification of CYP and CPR candidates  
 
CYP and CPR candidates were identified from rosemary transcriptome database 
(http://medicinalplantgenomics.msu.edu) and the RNA-Seq raw data of B. pendula and selfheal 
deposited in NCBI, using the corresponding reference sequences (listed in Supplementary Tables S1 and 
S2) as queries. 
To clone CYP and CPR genes from plants, total RNAs of rosemary tissues were isolated using the 
TRIzol reagent (Invitrogen) following the manufacturer’s instructions. cDNA of each RNA sample was 
synthesized using the SMARTerTM RACE 5’/3’ Kit (Takara Biomedical Technology Co., Ltd) according 
to product manual. Full-size sequences of truncated genes were obtained by rapid amplification of cDNA 
ends (RACE) using SMARTerTM RACE 5’/3’ Kit. The corresponding primers are listed in 
Supplementary Table S3. 
 
Phylogenetic analysis  
 
The phylogenetic tree was constructed, using the candidate CYPs of rosemary and the reference CYPs 
in Supplementary Table S1. Multiple sequence alignments were generated using the CLUSTAL W 
program. Phylogenetic analysis was conducted using the Maximum Likelihood method with MEGA7.0 
software (Kumar et al. 2016). Bootstrap analysis with 1000 replicates was used to assess the strength of 
the nodes in the tree (Jones et al. 1992). 
 
Construction of expression plasmids for functional elucidation 
 
AtLUP and ATR1 genes were amplified from Arabidopsis thaliana cDNA prepared following the same 
method as preparation of rosemary cDNA. 
All the gene fragments were amplified by PCR and ligated into the pEASY blunt cloning vector. 
The resulting plasmids were confirmed by gene sequencing. After digested, these gene fragments were 
respectively inserted into the corresponding MCSs of pESC-URA and pESC-LEU vectors to yield the 
plasmids pHJ01-pHJ07. The primers, resulting plasmids and yeast strains in this section are listed in 
Supplementary Tables S3-S5, respectively. 
 
Feeding experiments  
 
After a 24-hour fermentation, the cultures of the yeast stain HJ009 containing pHJ05 were suspended 
with authentic compounds (the final concentration of 4 mg/L) including lupeol, α-amyrin, β-amyrin and 
betulin, respectively, and then incubated at 30°C and 250 rpm for additional three days. The resulting 
cultures were extracted according to the method as described in the following section. 
 
Construction and fermentation of high-yield BA-producing yeasts  
 
To construct the expression cassettes, optiRoCYP01, RoCPR01 and optiAtLUP were inserted into the 
SexAI/AscI site of pM4-AtSQE2, pM2-tHMG1 and pM3-SynPgPPD by cut-and-paste method to obtain 
plasmids pM4-optiRoCYP01, pM2-RoCPR01 and pM3-optiAtLUP. To integrate optiRoCYP01, 
RoCPR01 and optiAtLUP into the NDT80 site of the strain WD2091 (Wang et al. 2018), five fragments 
were amplified from pM4-optiRoCYP01 (using primer set 3G-3-M-ADHt-TDH3-F/3G-3-M-TPI1t-
TEF1-R), pM3-optiAtLUP (using primer set 3G-2-M-TPI1t-TEF1-F/M-CYC1t-pEASY-R), pM2-
RoCPR01 (using primer set 1-M-pEASY-PGK1-F/3G-1-M-ADHt-TDH3-R) and pNDT80-HIS (using 
primer sets X1-M-pEASY-r-t-F/NDT80-interg-2 and NDT80-interg-1/X2-M-pEASY-r-t-R). These 
fragments were then transformed into strain WD2091 followed by selection on SD-HIS-URA-TRP plates 
to obtain the strain BA-1. Then, the second copy of the expression cassette of optiRoCYP01, RoCPR01 
and optiAtLUP was integrated into GAL80 site by transformation of BA-1 with the same three DNA 
fragments containing the corresponding expression cassettes as above and the other two fragments 
amplified from pGal80-LEU (using primer sets X1-M-pEASY-r-t-F/Gal80-interg-2 and Gal80-interg-
1/X2-M-pEASY-r-t-R). The resulting strains were selected on SD-HIS-URA-LEU-TRP plates to obtain 
BA-2. All the primers, plasmids and strains in this section are listed in Supplementary Tables S3-S5. 
 
Gene expression pattern analysis 
  
The expression pattern of RoCYP01 across various tissues of 4-month old rosemary plants was analyzed 
by quantitative reverse transcriptional polymerase chain reaction (qRT-PCR). Total RNA was isolated 
from roots, stems and leaves according to the method as mentioned above. All of RNA samples were 
treated with HiScript II qRTSuperMix II at 50 °C. The qRT-PCR experiments were performed on a 
Roche thermal cycler (LightCyler 480 II) in three independent biological replicates. The rosemary actin 
gene β-actin was amplified as an internal standard. All primers for qRT-PCR are shown in 
Supplementary Table S3. 
 
Extraction of triterpenoids from rosemary tissues and yeast cultures  
 
To investigate the accumulation of BA in different tissues of rosemary, fresh plant materials, including 
roots, stems and leaves, were ground to powders. 1 g of each powder was extracted with 20 mL of THF 
and ethanol mixture (v/v, 1:1) by sonication for 30 min. The extracts were centrifuged at 1000 rpm for 
10 min and the supernatants were collected. After repeating the extraction steps above 3 times, the 
supernatants were combined and concentrated to dryness by rotary evaporation. The residues were 
silylated for analysis by GC-MS.  
Engineered yeast cultures were separated into cells and media by centrifugation. After crushed, 
cells were extracted with ethyl acetate twice by sonication for 30 min. Media were partitioned by ethyl 
acetate twice. The cell and medium extraction solutions were pooled together, concentrated to dryness 
by rotary evaporation and silylated for GC-MS analysis. 
 
Cultivation in bioreactors  
 
Single colonies were inoculated into 100 mL shake flasks containing 15 mL SD medium lacking leucine, 
uracil, tryptophan and histidine, and incubated at 30°C and 250 rpm for 24 h to an OD600 between 2.0 to 
3.0. 50% Glycerol was added to culture media to a concentration of 25%, and 1 mL vials of cell 
suspension were stored at -80°C. Stored cells (1 ml) were thawed and transferred to a 250 mL shake flask 
containing 15 mL SD medium and incubated at 30°C and 250 rpm for 24 h, which was then transferred 
to three 1 L shake flasks containing 100 mL fermentation medium, respectively. Cells were cultivated at 
30 °C and 250 rpm for about 36 h to 48 h to an OD600 between 8.0 to 10.0. Fermentation medium used 
in this work was based on the medium described previously (Lenihan et al. 2008). All 300 mL culture 
was inoculated into a 5-liter fermentor (New Brunswick Scientific BioFlo 310) with 3 L fermentation 
medium. Fermentation was maintained at 30°C and pH 5.0 with addition of NH4OH. In an initial batch 
phase, dissolved oxygen (DO) was set to 30% and cascaded to agitation speed (from 300 to 1000 rpm) 
and air flow rate (from 3 to 20 L/min). After sugar and derived ethanol were consumed, the rise of DO 
upon 60% triggered pumping of feed medium (600 g/L glucose) to a final concentration of 5 g/L glucose 
in the fermentor in 3 minutes. As cell density increased, dissolved oxygen was allowed to reach 0% and 
the spacing between two feeds could be shorten to 30 minutes. 
 
GC-MS analysis of triterpenoids 
 
Each of the extracts above was treated with N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) at 
80 °C for 30 min prior to GC-MS analysis. GC-MS analysis was performed in an Agilent 7890B GC 
instrument equipped with an HP-5MS column and 5977B single quadrupole mass spectrometer in 
electron ionization (70 eV) mode. Samples (generally 1 μL) were injected in splitless mode at 80 °C and, 
after a 1 min hold, the temperature raised at 20 °C/min to 300 °C, where it was held for 15 min.  
To quantitative analysis of triterpenoid contents, a stock solution with a concentration of 1 mg/mL 
was accurately prepared for each authentic compound, and 100 μL stock solution was completely 
silylated. After dried, each silylated sample was resuspended by 1 mL hexane, from which 5-, 10-, 20-, 
40- and 80-fold diluted solutions were prepared to construct an external calibration curve by GC-MS. 
Lupeol correlation coefficient: y = 16615.5481x - 189.909, R2 = 0.9986; betulin correlation coefficient: 
y = 18793.1521x - 567.7013, R2 = 0.9981; BA correlation coefficient: y = 16247.8228x - 9223.9475, R2 
= 0.9995. 
 
Accession codes 
The cDNA sequences of the genes involved in this work have been deposited in GenBank (RoCYP01: 
MK592859; RoCYP02: MK592860; RoCYP03: MK592861; partial BpCYP01: MK592862; RoCPR01: 
MK592863; optiRoCYP01: MK592864; OptiAtLUP: MK592865). 
 
Results 
 
Identification of candidate CYPs capable of oxidizing lupeol into BA  
 
Birch species, such as B. pubescens, B. platyphylla, B. pendula and B. papyrifera, serve as the major 
sources of BA. Besides these, BA has been also found in many other plants (Pai and Joshi 2014; Ryu et 
al. 1992) – e.g. rosemary and selfheal (Prunella vulgaris). A well-assembled transcriptome database for 
rosemary has become available online (http://medicinalplantgenomics.msu.edu), and several versions of 
raw RNA-Seq datasets of B. pendula and selfheal have been released to NCBI as well. As the CYPs 
responsible for modifying triterpenoid backbones fall into CYP71, CYP72 and CYP85 clans 
(Thimmappa et al. 2014; Ghosh 2017), examples from each of the relevant (sub)families (Supplementary 
Table S1) were used as probes to identify homologs in the rosemary transcriptome and raw RNA-Seq 
data of B. pendula and selfheal. Two truncated (RoCYP01 and RoCYP02) and one full-length CYPs 
(RoCYP03) were found in the rosemary transcriptome; and a truncated CYP (BpCYP01) was assembled 
from the raw RNA-Seq data available for B. pendula. Rapid amplification of cDNA ends (RACE) was 
used to obtain full-length clones for RoCYP01 and RoCYP02. Unfortunately, a full-length clone for 
BpCYP01 was not obtained. 
Phylogenetic analysis of the obtained rosemary CYPs demonstrates that these all fall within the 
CYP85 clan (Fig. 1). More specifically, RoCYP01 clusters with the CYP716A subfamily that has been 
associated with BA biosynthesis and was assigned as CYP716A155 by Prof. David Nelson (Univ. Tenn.). 
By contrast, RoCYP02 and RoCYP03 are closer to CYPs that do not act in BA biosynthesis. Accordingly, 
RoCYP01 was hypothesized to be responsible for oxidizing lupeol into BA in rosemary.  
 
RoCYP01 expression and BA accumulation are correlated across various rosemary tissues  
 
To provide further support for the role of RoCYP01 as a physiologically relevant lupeol C-28 oxidase, 
its transcript levels were measured in leaves, stems and roots of rosemary by qRT-PCR. The highest 
RoCYP01 transcript level was observed in leaves, whereas its transcript levels in stems and roots were 
about 60% and 80% lower, respectively (Fig. 2). BA accumulation in leaves, stems and roots was also 
investigated by GC-MS analysis and found to be 28.4, 22.1 and 1.7 g/g (wet weight of tissues), 
respectively (Fig. 2). These results provide correlation between BA accumulation and the expression of 
RoCYP01, supporting a role for this in rosemary BA biosynthesis. 
 
Functional characterization of RoCYP01  
 
The utility of a synthetic biology approach towards clarifying enzymatic function in plant terpenoid 
biosynthesis has been previously demonstrated (Zi and Peters 2013; Zi et al. 2014; Ignea et al. 2016), in 
particular, via reconstruction of the upstream metabolic pathway to produce putative substrate(s) for the 
enzyme of interest. Here this approach was enabled by cloning of a lupeol synthase encoding gene from 
Arabidopsis thaliana (AtLUP) into the yeast expression vector pESC-LEU to yield pHJ01, 
transformation of which into Saccharomyces cerevisiae BY4741 led to the lupeol-producing strain HJ001. 
To enable CYP activity a cytochrome P450 reductase (CPR) encoding gene from A. thaliana (AtCPR1) 
was cloned into pESC-URA, along with RoCYP01 (as controls RoCYP02 and RoCYP03 were similarly 
cloned), leading to pHJ02 (as well as pHJ03 and pHJ04). These were transformed together with pHJ01 
into S. cerevisiae BY4741 to obtain yeast strains HJ002-HJ004 (Supplementary Table S5). Unfortunately, 
none of these produced BA. Given that CYP/CPR pairs from the same plant species have been shown to 
exhibit higher efficiency than non-native combinations (Guo et al. 2013), it was hypothesized that use of 
rosemary CPR might enable activity. Accordingly, characterized plant CPRs (Supplementary Table S2) 
were used as probes to identify homologs in the rosemary transcriptome. Only one full-length CPR 
candidate was identified. This RoCPR1 was cloned in place of AtCPR1 in pHJ02-pHJ04 to construct 
pHJ05-pHJ07 (Supplementary Table S4), respectively. These were co-transformed with pHJ01 into S. 
cerevisiae BY4741 to obtain yeast strains HJ005-HJ007 (Supplementary Table S5), respectively. BA was 
detected from the extract of the strain HJ005, in which AtLUP was co-expressed with RoCPR1 and 
RoCYP01 (Fig. 3).  
As many CYPs involved in triterpenoid biosynthesis are promiscuous in terms of their substrate 
specificity (Thimmappa et al. 2014; Ghosh 2017), to further support a role for RoCYP01 its substrate 
preference also was investigated here. This was accomplished by transforming just pHJ05 for co-
expression of RoCPR1 and RoCYP01 to obtain yeast strain HJ009 (Supplementary Table S5), which was 
then fed lupeol, -amyrin, -amyrin or betulin. The results indicated that although RoCYP01 can oxidize 
-amyrin and -amyrin into ursolic acid and oleanolic acid (Figs. 4c and 4d), respectively, it shows the 
highest efficiency in transformation of lupeol into BA (Fig. 4a). Interestingly, RoCYP01 prefers lupeol 
to betulin as well (Fig. 4b), suggesting that betulin might be a transient intermediate retained in the active 
site during the requisite series of reactions. Regardless, these results strongly indicate that RoCYP01 is 
the lupeol C-28 oxidase involved in rosemary BA biosynthesis. 
 
Optimization of yeast BA production 
 
It has previously been shown that high-level production of plant-derived terpenoids in a microbial host 
requires elucidation of the relevant enzymes (Paddon et al. 2013). Moreover, it also has been shown that 
modular pathway engineering is an efficient means to rapidly construct such high-yielding microbial 
strains for such natural products (Paddon et al. 2013; Wong et al. 2018; Zhou et al. 2012; Ajikumar et al. 
2010). Thus, building on identification of RoCYP01 as a BA specific lupeol C-28 oxidase, this approach 
was taken here to increase yeast BA production levels.  
As in previous studies (Dai et al. 2013; Dai et al. 2014; Wang et al. 2018), the upstream steps of the 
innate (tri)terpenoid biosynthetic pathway in yeast were arbitrarily divided into two modules (Fig. 5). 
The first of these corresponds to the mevalonate-dependent (MVA) pathway for production of the 
universal isoprenoid/terpenoid precursors isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP) from the central metabolite acetyl-CoA. This module was optimized by overexpression of all 
the corresponding enzymes, although a truncated version of HMG (expressing just the catalytic domain) 
was used as this has been shown to increase flux (Donald et al 1997; Engels et al 2008), as previously 
described (Dai et al. 2013; Dai et al. 2014; Wang et al. 2018). The second module corresponds to the 
subsequent production of the common triterpenoid precursor 2,3-oxidosqualene (oxSQ). This module 
also was optimized as previously described (Wang et al. 2018). Briefly, by overexpression of a squalene 
synthase and squalene-epoxidase from A. thaliana (AtSQS2 and AtSQE2, respectively), as well as an 
FPP synthase from Salvia miltiorrhiza (SmFPS). Together, these optimized MVA and oxSQ modules 
provide significant increase of triterpenoid production levels (Wang et al. 2018).  
For the production of BA specifically, the final module was targeted at improvement of the 
expression of RoCYP01 and AtLUP. For this purpose, synthetic genes, codon optimized for expression 
in yeast were obtained (optiRoCYP01 and optiAtLUP). Three expression cassettes, PPGK1-RoCPR1-TADH1, 
PTDH3-optiRoCYP01-TTPI1 and PTEF1-optiAtLUP-TCYC1 (BA module) were constructed according to the 
previously reported method (Dai et al. 2013), and these were integrated into the NDT80 site of a yeast 
strain in which the optimized MVA and oxSQ modules were already present (i.e., by integration into 
HIS3 and GAL7 sites of the yeast chromosome), to yield the strain BA-1 (Supplementary Table S5). After 
flask fermentation, BA-1 was found to produce 24.7, 99.3 and 21.7 mg/L of lupeol, betulin and BA, 
respectively (Fig. 6). We then inserted a second copy of the BA module into the GAL80 site of BA-1 to 
construct the strain BA-2 (Supplementary Table S5). This led to an approximately ten-fold increase in 
BA yield (193.5 mg/L), with high yields of lupeol and betulin as well (23.6 and 59.5 mg/L), respectively; 
Fig. 6). Finally, the BA-2 strain of yeast was cultured in a fed-batch fermentation and, after a 168-h 
fermentation, titers of 0.1, 1.0 and 1.5 g/L of lupeol, betulin and BA (respectively) were observed. 
Notably, the co-production of betulin further increases the potential yield, as this can be relatively easily 
converted to BA (Pezzuto and Kim 1998; Csuk et al. 2006; Tulisalo et al. 2013; Ressmann et al. 2017). 
  
Discussion 
 
BA and its derivatives have exhibited strong potential for development into anticancer and anti-HIV 
drugs. However, if this potential is realized it will be necessary to provide large-scale access to a more 
reliable and less resource intensive source of BA. One promising method for accessing such plant-derived 
terpenoid natural products is via a synthetic biology approach – i.e., biotechnological production via 
engineered microbes (Li and Pfeifer 2014; Bian et al 2017). However, as previously demonstrated for 
high-level production of arteminisic acid (Paddon et al. 2013), this requires identification of the relevant 
enzymes. While it has been shown that a number of CYP716A subfamily members can oxidize lupeol 
into trace amounts of BA, their major functions in planta seem to be conversion of - and -amyrin into 
ursolic acid and oleanolic acid, respectively (Fukushima et al. 2011; Huang et al. 2012). More recently, 
CYP716A180 was reported to selectively catalyze the oxidation of lupeol to BA (Zhou et al. 2016). 
However, this has not yet led to construction of a high-yielding microbial strain suitable for 
biotechnological production of BA.  
Here publicly available transcriptome data for rosemary was used to rapidly identify RoCYP01 as 
a potential lupeol C-28 oxidase responsible for the observed production of BA by this plant, including 
not only phylogenetic analysis (Fig. 1), but also correlated expression (Fig. 2). Building on previous use 
of a synthetic biology approach to elucidation of plant terpenoid biosynthesis by upstream pathway 
reconstruction in Escherichia coli (Zi and Peters 2013; Zi et al. 2014; Boutanaev et al. 2015), RoCYP01 
was investigated by a similar approach in yeast, which is more amenable to triterpenoid production. 
While requiring use of the rosemary RoCPR1, it was thus possible to demonstrate that RoCYP01 
selectively reacts with lupeol, relative to -amyrin, -amyrin, or even betulin, which is the alcoholic 
intermediate in conversion of lupeol to BA (Figs. 3 and 4).  
Identification of RoCYP01 as the rosemary lupeol C-28 oxidase for BA biosynthesis via this 
approach further encouraged construction of a high-yielding strain. This builds on previous work 
demonstrating not only how flux can be increased to isoprenoids/terpenoids (Dai et al. 2013; Dai et al. 
2014; Wang et al. 2018), but triterpenoids more specifically (Wang et al. 2018). In particular, for 
production of the common triterpenoid precursor 2,3-oxidosequalene. This was coupled to optimization 
of the genes specific to BA biosynthesis, which led to titers of >1 g/L in batch-fed culture. To the best of 
our knowledge, this is the highest BA yield so far achieved by microbial fermentation. Accordingly, this 
work provides a good example of the rapid exploitation of the increasing amounts of sequence 
information available for plants to not only provides insights into biosynthetic pathways, but also facile 
synthetic biology approaches towards enabling biotechnological production of valuable natural products 
such as BA and its derivatives.  
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Figure Legends 
 
Figure 1. Phylogenetic analysis of the CYPs cloned from rosemary. RoCYP01, RoCYP02 and 
RoCYP03, as well as the CYPs involved in biosynthesis of plant triterpenoids (Thimmappa et al. 2014; 
Supplementary Table S1) were included to construct the tree via maximum likelihood analysis. The blue 
ones are the CYPs which can oxidize lupeol into BA, and the red ones are the CYPs identified from 
rosemary in this study. The bluish, blue, fuchsia and green shaded CYPs belong to CYP71, CYP72, 
CYP51 and CYP85 subfamilies, respectively.  
 
Figure 2. Correlation between expression patterns of RoCYP01 and BA accumulation in rosemary 
tissues. Green bars: the mRNA levels of RoCYP01 relative to those of the rosemary actin gene β-actin 
across leaves, stems and roots of rosemary, respectively; blue bars: BA accumulation across leaves, stems 
and roots of rosemary, respectively. The error bars indicate the SD from triplicate biological replicates 
 
Figure 3. GC-MS analysis of the extracts of the engineered yeasts. (a) and (b) are the extracts of 
HJ005 expressing AtLUP, RoCYP01 and RoCPR1, and HJ008 expressing AtLUP and RoCPR1 
(Supplementary Table S5), respectively. (c), (d) and (e) are the authentic compounds lupeol, betulin and 
BA. (f), (g) and (h) are the mass spectra of .lupeol, betulin and BA, respectively. All the samples are 
silylated before GC-MS analysis. 
 
Figure 4. Investigation of substrate selectivity of RoCYP01. GC-MS analysis of the extracts of the 
yeast containing pHJ05 incubated with lupeol (a), betulin (b), -amyrin (c) and -amyrin (d), respectively. 
(e), (f), (g) and (h) are the mass spectra of -amyrin, -amyrin, ursolic acid (UA) and oleanolic acid 
(OA), respectively. All the samples are silylated before GC-MS analysis. (i) is the scheme which 
illustrates that RoCYP01 catalyzing oxidation reactions, using lupeol, -amyrin and -amyrin as 
substrates, respectively.  
 
Figure 5. Biosynthetic pathway of BA in the engineered yeasts.  
 
Figure 6. The yields of lupeol, betulin and BA of BA-1 and BA-2. BA-1 and BA-2 possess one and 
two copies of PPGK1-RoCPR01-TADH1-PTDH3-optiRoCYP01-TTPI1-PTEF1-optiAtLUP-TCYC1, respectively 
(Supplementary Table S5). The error bars indicate the SD from three independent fermentation 
experiments. 
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Table S1. The reference CYPs from plants 
Clan Gene Species 
GenBank 
ID 
Substrate Function 
CYP71 
CYP71A16 Arabidopsis thaliana NP_199073 Marneral, marnerol C-23 hydroxylation 
CYP71D353 Lotus japonicus KF460438 
Dihydrolupeol, 
20-hydroxylupeol 
C-20 hydroxylation, 
C-28 oxidation 
(three-step oxidation) 
CYP93E1 Glycine max BAE94181 β-Amyrin, sophoradiol C-24 hydroxylation 
CYP93E2 Medicago truncatula ABC59085 β-Amyrin C-24 hydroxylation 
CYP93E3 Glycyrrhiza uralensis BAG68930 β-Amyrin C-24 hydroxylation 
CYP705A1 Arabidopsis thaliana NP_193268 Arabidiol C-15–C-16 cleavage 
CYP705A5 Arabidopsis thaliana Q9FI39 7β-Hydroxythalianol C-15–C-16 desaturation 
CYP72 
CYP72A61v2 Medicago truncatula BAL45199 24-Hydroxy-β-amyrin C-22 hydroxylation 
CYP72A63 Medicago truncatula BAL45200 β-Amyrin 
C-30 hydroxylation, 
C-30 oxidation 
(three-step oxidation) 
CYP72A154 Glycyrrhiza uralensis BAL45207 
β-Amyrin, 
11-oxo-β-amyrin 
C-30 hydroxylation (β-amyrin); C-
30,C-22, and C-29 
Oxidation (11-oxo-β-amyrin) 
CYP72A67 Medicago truncatula ABC59075 Oleanolic acid C-2β hydroxylation 
CYP72A68v2 Medicago truncatula BAL45204 Oleanolic acid 
C-23 hydroxylation 
(three-step oxidation) 
CYP51 CYP51H10 Avena strigosa ABG88961 β-Amyrin 
C-16 hydroxylation, 
C-12–C-13 epoxidation 
CYP85 
CYP88D6 Glycyrrhiza uralensis BAG68929 
β-Amyrin, 
30-hydroxy-amyrin 
C-11 oxidation 
(two-step oxidation) 
CYP87D16 Maesa lanceolata AHF22090 β-Amyrin C-16α Oxidation 
CYP708A2 Arabidopsis thaliana Q8L7D5 Thalianol C-7 hydroxylation 
CYP716A47 Panax ginseng AEY75217 Dammarenediol II C-12 hydroxylation 
CYP716Y1 Bupleurum falcatum AHF45909 β-Amyrin, α-amyrin C-16α Oxidation 
CYP716A141 
Platycodon 
grandiflorus 
BAX04008 β-Amyrin C-16β Oxidation 
CYP716A53v2 Panax ginseng AFO63031 Protopanaxadiol C-6 hydroxylation 
CYP716A111 Aquilegia coerulea APG38190 β-Amyrin C-16β Oxidation 
CYP716A80 Barbarea vulgaris ALR73782 
β-Amyrin, 
α-amyrin, lupeol 
C-28 oxidation 
(three-step oxidation) 
CYP716A81 Barbarea vulgaris ALR73781 
β-Amyrin, 
α-amyrin, lupeol 
C-28 oxidation 
(three-step oxidation) 
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CYP716A1 Arabidopsis thaliana AED94045 
β-Amyrin, 
α-amyrin, lupeol 
C-28 oxidation 
 
 
CYP716A2 Arabidopsis thaliana AED94048 
β-Amyrin, 
α-amyrin, lupeol 
C-16,C-22α,C-28 Oxidation 
CYP716A12 Medicago truncatula ABC59076 
β-Amyrin, 
α-amyrin, lupeol 
C-28 oxidation 
(three-step oxidation) 
CYP716A179 Glycyrrhiza uralensis BAW34647 
β-Amyrin, 
α-amyrin, lupeol 
C-28 oxidation 
(three-step oxidation) 
CYP716A14v2 Artemisia annua AHF22083 
β-amyrin, α-amyrin, 
lupeol 
C-3 oxidation 
CYP716A140v2 
Platycodon 
grandiflorus 
BAX04007 β-amyrin 
C-28 oxidation 
(three-step oxidation) 
CYP716A75 Maesa lanceolata AHF22088 β-Amyrin 
C-28 oxidation 
(three-step oxidation) 
CYP716A52v2 Panax ginseng AFO63032 β-amyrin 
C-28 oxidation 
(three-step oxidation) 
CYP716A244 
Eleutherococcus 
senticosus 
APZ88353 β-Amyrin 
C-28 oxidation 
(three-step oxidation) 
CYP716AL1 Catharanthus roseus AEX07773 
β-Amyrin, 
α-amyrin, lupeol 
C-28 oxidation 
(three-step oxidation) 
CYP716A78 Chenopodium quinoa ANY30853 β-Amyrin 
C-28 oxidation 
(three-step oxidation) 
CYP716A79 Chenopodium quinoa ANY30854 β-Amyrin 
C-28 oxidation 
(three-step oxidation) 
CYP716A15 Vitis vinifera BAJ84106 
β-Amyrin, 
α-amyrin, lupeol 
C-28 oxidation 
(three-step oxidation) 
CYP716A17 Vitis vinifera BAJ84107 β-Amyrin 
C-28 oxidation 
(three-step oxidation) 
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Table S2. The reference CPRs from plants 
CPRs species GenBank ID 
Ob-CPR1 Ocimum basilicum KX192385 
Pc-CPR Perilla citriodora LC325999 
Pf-CPR Perilla frutescens GQ120439 
Sm-CPR1 Salvia miltiorrhiza FR693803 
Pk-CPR Picrorhiza kurrooa JN968968 
Sd-CPR Scoparia dulcis KF306080 
Sm-CPR2 Salvia miltiorrhiza JX848592 
Ob-CPR2 Ocimum basilicum KX192386 
Si-CPR1 Sesamum indicum LC209223 
AtCPR1 Arabidopsis thaliana NM_118585 
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Table S3. The primers used in this study 
Name Sequence Description 
For RACE experiments 
 
RoCYP01-5’end-
1 
GGCCAGGTCGGCCTTCCGC
TGCTTGATG 
The gene specific primer of first 
round PCR for amplification of 5’-
end of RoCYP01 
RoCYP01-5’end-
2 
GGTCCATGATGCCAACGTA
GCGGTGGAG 
The gene specific primer of second 
round PCR for amplification of 5’-
end of RoCYP01 
RoCYP01-3’end-
1 
GGACGCCGTTCCACAAGGG
GATCAAGGC 
The gene specific primer of first 
round PCR for amplification of 3’-
end of RoCYP01 
RoCYP01-3’end-
2 
GCTCGTCGCCATCATCAAG
CAGCGGAAG 
The gene specific primer of second 
round PCR for amplification of 3’-
end of RoCYP01 
RoCYP02-5’end-
1 
CGTTCTCCAAGGCTCTTCA
GCAGCATCG 
The gene specific primer of first 
round PCR for amplification of 5’-
end of RoCYP02 
RoCYP02-5’end-
2 
GCAACGCTGGACGTGTCGT
GGCCTGC 
The gene specific primer of second 
round PCR for amplification of 5’-
end of RoCYP02 
RoCPR01-3’end-
1 
GCCACCTCCATTCCCCCCTT
GCACTTTG 
The gene specific primer of first 
round PCR for amplification of 3’-
end of RoCPR01 
RoCPR01-3’end-
2 
GTTCCCGTCCGCCAAGCCT
TCTCTAGG 
The gene specific primer of second 
round PCR for amplification of 3’-
end of RoCPR01 
 
For gene cloning 
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EcoRI-
RoCYP01-f 
GAATTCATGGAGTTCTTCTA
TGCTTCCCTC 
The forward primer for cloning of 
RoCYP01 
NotI-RoCYP01-r GCGGCCGCTTAAGAAGTGT
GGGGGTAGAGTCG 
The reverse primer for cloning of 
RoCYP01 
EcoRI-
RoCYP02-f 
GAATTCATGGCTGAAATAC
TTTTGATGC 
The forward primer for cloning of 
RoCYP02 
NotI-RoCYP02-r GCGGCCGCCTATGTCTGTG
GTTGGATAAGAATG 
The reverse primer for cloning of 
RoCYP02 
EcoRI-
RoCYP03-f 
GAATTCATGGAGCTCCTAA
CGTTAGCTG 
The forward primer for cloning of 
RoCYP03 
ClaI-RoCYP03-r ATCGATTCACTGTTTGTAAA
GGCGGAC 
The reverse primer for cloning of 
RoCYP03 
BamHI-
RoCPR01-f 
GGATCCATGGAACCCTCGT
CGCCGAAGCTC 
The forward primer for cloning of 
RoCPR01 
KpnI-RoCPR01-
r 
GGTACCTCACCATACATCGC
GCAAATATCTTCCTG 
The reverse primer for cloning of 
RoCPR01 
SrfI-ATR1-f GCCCGGGCATGACTTCTGC
TTTGTATGCTTCCG 
The forward primer for cloning of 
ATR1 
KpnI-ATR1-r GGTACCTCACCAGACATCT
CTGAGGTATCTTCC 
The reverse primer for cloning of 
ATR1 
BamHI-AtLUP-f GGATCCATGTGGAAGTTGA
AGATAGGAAAGG 
The forward primer for cloning of 
AtLUP 
KpnI-AtLUP -r GGTACCTTAATTAACGATAA
ACACAACTTTTCG 
The reverse primer for cloning of 
AtLUP 
 
For qRT-PCR 
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qRT-RoCYP01-f CCTTCAGGGTGCATTCAGA
GAAGC 
 
qRT-RoCYP01-r CGAACCTCGACGGATCGAA
CTTC 
 
qRT--actin-f GAAGGTTATGCACGCCCTC
ACG 
 
qRT--actin-r CAATTTCCCGCTCTGCAGT
GG 
 
 
For construction of expression cassettes 
 
SexAI-
optiRoCYP01-f 
GCGACCTGGTAAAACAATG
GAATTTTTCTATGCATC 
For cloning optiRoCYP01 into 
pM4-AtSQE2 
optiRoCYP01-
AscI-r 
GCGGGCGCGCCTTAAGAAG
TATGTGGGTATAATC 
For cloning optiRoCYP01 into 
pM4-AtSQE2 
SexA1-
RoCPR01-f 
GCGACCTGGTAAAACAATG
GAACCCTCGTCGCC 
For cloning RoCPR01 into pM2-
tHMG1 
RoCPR01-AscI-r GCGGGCGCGCCTCACCATA
CATCGCGCAAATATC 
For cloning RoCPR01 into pM2-
tHMG1 
SexAI-
optiAtLUP-f 
GCGACCTGGTAAAACAATG
TGGAAGTTGAAGATAGG 
For cloning optiRoAtLUP into 
pM3-SynPgPPD 
optiAtLUP-AscI-
r 
GCGGGCGCGCCTTAGTAGG
AGTGAGCACATAAAAC 
For cloning optiRoAtLUP into 
pM3-SynPgPPD 
 
Primers used in DNA assembly 
 
1-M-pEASY-
PGK1-F 
CTGTTTCCTGTGTGAAATTG
TTATCCGCTCACAATTCCAC
ACAACATACGAGCCTTAAT
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TAAACGCACAGATATTATAA
C 
3G-1-M-ADHt-
TDH3-R 
CCTCCGCGTCATTAAACTTC
TTGTTGTTGACGCTAACATT
CAACGCTAGTATTCGGCAT
GCCGGTAGAGGTGTGG 
 
3G-3-M-ADHt-
TDH3-F 
CAGGTATAGCATGAGGTCG
CTCTTATTGACCACACCTCT
ACCGGCATGCCGAATACTA
GCGTTGAATGTTAGCGTC 
 
3G-3-M-TPI1t-
TEF1-R 
AGGAGTAGAAACATTTTGA
AGCTATGGTGTGTGGGGGA
TCACTTTAATTAA 
TCTATATAACAGTTGAAATT
TGGA 
 
3G-2-M-TPI1t-
TEF1-F 
GTCATTTTCGCGTTGAGAA
GATGTTCTTATCCAAATTTC
AACTGTTATATAGATTAATT
AAAGTGATCCCCCACAC 
 
M-CYC1t-
pEASY-R 
CGTATTACAATTCACTGGCC
GTCGTTTTACAACGTCGTG
ACTGGGAAAACCCTGGCGC
GTTGGCCGATTCATTAATGC 
 
X1-M-pEASY-r-
t-F 
CTTGCAAATGCCTATTGTGC
AGATGTTATAATATCTGTGC
GTTTAATTAAGGCTCGTATG
TTGTGTGGAATTGT 
 
X2-M-pEASY-r-
t-R 
CGAAGGCTTTAATTTGCAA
GCTGCGGCCCTGCATTAAT
GAATCGGCCAACGCGCCAG
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GGTTTTCCCAGTCACGACG
TTG 
NDT80-interg-1 CATCATAAGGAATTCCGGG
ATTCTCCCCAT 
 
NDT80-interg-2 CTGGCTTTAAAAAATGGAT
AAAAAGGGATG 
 
Gal80-1-interg-1 GGTTACCAGATCTACACCG
TTCCCGATTTCA 
 
Gal80-2-interg-2 ACAACATTTGGTCACTAAA
TCGATATTTTAC 
 
X1-M-pEASY-r-
t-F 
CTTGCAAATGCCTATTGTGC
AGATGTTATAATATCTGTGC
GTTTAATTAAGGCTCGTATG
TTGTGTGGAATTGT 
 
X2-M-pEASY-r-
t-R 
CGAAGGCTTTAATTTGCAA
GCTGCGGCCCTGCATTAAT
GAATCGGCCAACGCGCCAG
GGTTTTCCCAGTCACGACG
TTG 
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Table S4. The plasmids involved in this study 
Name Description Source 
pEASY-Blunt  TransGen 
Biotech 
p-RoCYP01 Clone EcoRI-RoCYP01-NotI into pEASY-
Blunt 
This study 
p-RoCYP02 Clone EcoRI-RoCYP02-NotI into pEASY-
Blunt 
This study 
p-RoCYP03 Clone EcoRI-RoCYP02-ClaI into pEASY-
Blunt 
This study 
p-RoCPR01 Clone BamHI-RoCYP02-KpnI into pEASY-
Blunt 
This study 
p-ATR1 Clone srfI-ATR1-KpnI into pEASY-Blunt This study 
p-AtLUP Clone BamHI-AtLUP-KpnI into pEASY-Blunt This study 
pM2-tHMG1 Clone PPGK1-SexAI-tHMG1-AscI-TADH1 into 
pEASY-Blunt 
(Dai et al., 
2013) 
pM2-RoCPR01 Clone RoCPR01 into the SexAI/AscI site of 
pM2-tHMG1 
This study 
pM3-synPgPPD Clone PTEF1-SexAI-synPgPPD-AscI-TCYC1 into 
pEASY-Blunt 
(Dai et al., 
2013) 
pM3-optiAtLUP Clone optiAtLUP into the SexAI/AscI site of 
pM3-synPgPPD 
This study 
pM4-AtSQE2 Clone PTDH3-SexAI-AtSQE2-AscI-TTPI1 into 
pEASY-Blunt 
(Wang et al., 
2018) 
pM4-
optiRoCYP01 
Clone optiRoCYP01 into the SexAI/AscI site 
of pM4-AtSQE2 
This study 
 
 
12 
 
pEASY-Blunt 
simple 
 TransGen 
Biotech 
pNDT80-HIS Clone NDT80 and HIS3 marker into pEASY-
Blunt simple 
(Wang et al., 
2018) 
pGal80-LEU Cloning GAL80 and LEU2 marker into 
pEASY-Blunt simple 
(Wang et al., 
2018) 
pESC-LEU   
pHJ01 Clone AtLUP into the BamHI/KpnI site of 
pESC-LEU 
This study 
pESC-URA   
pESC-URA-ATR1 ATR1 in the SrfI/KpnI site of pESC-URA This study 
pHJ02 RoCYP01 is cloned into the EcoRI/NotI site of 
pESC-URA-ATR1 
This study 
pHJ03 RoCYP02 is cloned into the EcoRI/NotI site of 
pESC-URA-ATR1 
This study 
pHJ04 RoCYP03 is cloned into the EcoRI/ClaI site of 
pESC-URA-ATR1 
This study 
pESC-URA-
RoCPR01 
RoCPR01 in the BamHI/KpnI site of pESC-
URA 
This study 
pHJ05 RoCYP01 is cloned into the EcoRI/NotI site of 
pESC-URA-RoCPR01 
This study 
pHJ06 RoCYP02 is cloned into the EcoRI/NotI site of 
pESC-URA-RoCPR01 
This study 
pHJ07 RoCYP03 is cloned into the EcoRI/ClaI site of 
pESC-URA-RoCPR01 
This study 
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Table S5. The yeast strains involved in this study 
Name Description Source 
S. cerevisiae 
BY4741 
MAT, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0 ATCC 
S. cerevisiae 
CEN.PK2-1D 
MATα, ura3-52, leu2-3_112, trp1-289, his3Δ, 
MAL2-8c, SUC2 
This lab 
collection 
HJ001 S. cerevisiae BY4741 with pHJ01 This studya 
HJ002 S. cerevisiae BY4741 with pHJ01 and pHJ02 This studya 
HJ003 S. cerevisiae BY4741 with pHJ01 and pHJ03 This studya 
HJ004 S. cerevisiae BY4741 with pHJ01 and pHJ04 This studya 
HJ005 S. cerevisiae BY4741 with pHJ01 and pHJ05 This studya 
HJ006 S. cerevisiae BY4741 with pHJ01 and pHJ06 This studya 
HJ007 S. cerevisiae BY4741 with pHJ01 and pHJ07 This studya 
HJ008 S. cerevisiae BY4741 with pHJ01 and pESC-URA-
RoCPR01 
This studya 
HJ009 S. cerevisiae BY4741 with pHJ05 This studya 
WD-2091 S. cerevisiae CEN.PK2-1D, 
HIS3::TRP1-PPGK1-AtSQS2-TADH1-PTDH3-AtSQE2-
TTPI1-PTEF1-SmFPS-TCYC1 
Gal7::URA3-PPGK1-tHMG1-TADH1-PPDC1-ERG12-
TADH2-PENO2-IDI1-T-PDC1-PPYK1-ERG19-TPGI1-PFBA1-
ERG13-TTDH2-PTDH3-ERG8-TTPI1--PTEF1-ERG10-
TCYC1 
(Wang et 
al., 2018)b 
BA-1 WD-2091, 
NDT80::HIS3-PPGK1-RoCPR01-TADH1-PTDH3-
optiRoCYP01-TTPI1-PTEF1-optiAtLUP-TCYC1 
This studyb 
BA-2 BA-1, 
GAL80::LEU2-PPGK1-RoCPR01-TADH1-PTDH3-
optiRoCYP01-TTPI1-PTEF1-optiAtLUP-TCYC1 
This studyb 
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a All these yeast strains are deposited in Microbiolagical Culture Collection Center of Jinan 
University, the collection numbers are JNU-JZ-HJ001, JNU-JZ-HJ002, JNU-JZ-HJ003, JNU-JZ-
HJ004, JNU-JZ-HJ005, JNU-JZ-HJ006, JNU-JZ-HJ007, JNU-JZ-HJ008 and JNU-JZ-HJ009; 
b All these yeast strains are deposited in Microbiolagical Culture Collection Center of Tianjin 
Institute of Industrial Biotechnology, the collection numbers are WD-2091, WD-2091-BA-1 and 
WD-2091-BA-2. 
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The sequence of RoCYP01 
ATGGAGTTCTTCTATGCTTCCCTCCTCTGCCTCTTCGTCTCCCTGGTCTTCCTCTCCCT
CCACCTCCTCTTTTATAAGACGAAGACCGGCTCCCTCCCCCCGGGCAAGACCGGGTG
GCCGGTGATCGGGGAGAGCCTCGAGTTCCTCTCCACCGGCTGGAAGGGCCACCCAGA
GAAGTTCATCTTCGACCGGATGGCCCGCTACTCCTCCCACGTCTTCCGCACCCACCTC
CTCGGCGAGCCGGCCGCTGTCCTCTGCGGCTCCGCCGGCAACAAGTTCCTCTTCTCCA
ACGAGAACAAGCTCGTCCAAGCGTGGTGGCCGAGCTCCGTCGAGAAGATCTTCCCCA
ACGACAACGCCGAGACATCCTCGAAGGAAGAGTCCATCAAGATGCGCCGCATGCTC
CCCACCTTCTTCAAGCCGGAGGCCCTCCACCGCTACGTTGGCATCATGGACCACATT
GCCCGCCGCCACTTCGCCGACGGCTGGGACGGCAAACGGGAGGTCGTCGTCTTCCCC
TTGGCCAAGAACTACACCTTCTGGCTCGCCTGCCGCCTCTTTCTCAGCGTCGAGGATC
CCTCGCAGGTCGAAAAATTCGCGGCCCCGTTCAATCTTTTAGCATCGGGGCTGATCTC
GATCCCGATCGATCTGCCCGGGACGCCGTTCCACAAGGGGATCAAGGCCTCCGCCTA
CATCAGGAAGGAGCTCGTCGCCATCATCAAGCAGCGGAAGGCCGACCTGGCCGACG
GCACGGCGTCACCGACGCAGGACATCCTGTCGCACATGCTGCTCACCAGCAACGAAG
ATGGGAAATTCATGCAGGAGTCGGACATCGCGAACAAGATTCTGGGTTTGCTCATTG
GCGGCCATGACACTGCTAGCTCTGCTTGTACCTTCGTCGTCAAGTACCTCGCCGAGTT
GCCCCAGGTCTACGAGGGCGTCTACAAAGAGCAAATGGAGATCGCGAAATCAAAGG
CGGCCGGAGAGTTGCTGAACTGGGAGGACTTGCAGAAGATGAAGTACTCATGGAAC
GTTGCATGCGAAGTGCTGAGACTCGCACCGCCCCTTCAGGGTGCATTCAGAGAAGCC
CTTGCCGATTTCTCATTCAATGGCTTCTCCATCCCAAAGGGCTGGAAGTTATATTGGA
GTGCAAATTCGACGCACAAGAACTCGGAGTTCTTCCCGGAGCCGGAGAAGTTCGAT 
CCGTCGAGGTTCGAGGGGTCGGGACCCGCCCCGTACACGTTCGTGCCGTTCGGCGGC
GGGCCGAGGATGTGCCCCGGCAAGGAATATGCCCGTTTGGAAATCCTAGTGTTCATG
CACCACCTTGTGAAGAGGTTCAAGTGGGAGAAGATGATTCCTGATGAGAAAATTGTG
GTTGATCCAATGCCCATTCCGGCTAATGGTCTCCCAGTTCGACTCTACCCCCACACTT
CTTAA  
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The sequence of RoCYP02 
ATGGCTGAAATACTTTTGATGCTTGCAGCATTTTTGATAATCTTGGTCATAATAATTT
TCTCAAATAGGACGAGGTGTTCAAGAAACGGGGCCTTGAATCTGCCTCCGGGCAGCT
ATGGGTGGCCGGTTCTTGGGGAAACGGTTGAGTTCCTCCGTGCTGGATTGGATGGGA
CGCCGGAGAAATTTGTTAGAGAGAGAATGGAGAAATACAAGTCGCAAGTTTTCAAG
ACATGGATCATGGGGGAGCCCATGGCCGTTTTGTGTGGAGCTGCAGGTAACAAATTC
TTGTTCAGCAATGAAAAGAAGCTGGTGACAGTGTGGTGGCCGAGCTCCGTGAGGAAT
CTGCTGGGGCCGTGCTTGGCCACAAGCGGCGGCGATGAAGGCCGCCAGATGAGGAG
GATGGTGTCGTATTTCGTGAGCCCTGATGCTTTCACGAGGCTTTATATCAAGACAATG
GATATGGTCTCCCAGCAGCATATCAAGATTAACTGGCAAGGTAAAGAAGAGGTCAA
AGTGTTTCCGACGATCAAGTTGTACACGTTTGAACTTGCATGTAGACTGTTTATGAGC
CTTGAAGATGGCGAGCAGATTGGGAAGCTTGCTACTTTGTTTAATATTTTCTTGAAAG
GGATAATCTCAATCCCTATCAATTTGCCTGGAGCAAGATTCTACAGAGCAAAGAAAG
CTACATCTGCTATCAAGAATGAACTGCACAAGTTAGTGAGAGATAGACGAGGTGCTT
TGGAGCAGAAAACAGCTCTGCCCTCCCAAGATCTTCTCTCTCATCTGCTAGTAACCCC 
TGATGAGAATGGCAAGTTCATGACTGAATCGGTAATCGTGAACAACATACTGATGCT
GCTCTTTGCAGGCCACGACACGTCCAGCGTTGCAATAACGATGCTGCTGAAGAGCCT
TGGAGAACGTCCTGATGTTTATGAGAAGGTGTTGAGAGAGCAGAAGGAGATAGCAT
CATCGGAAGGGGAGTTTCTGCAGTGGGAGGACATACAGAAGATGAAGTACTCGTGG
AGCGTGGTATGTGAAGTGACGAGGCTGTCACCGCCAGTCATTGGTGCTTTCAGAGAA
GCGTTAACGGACATAAGCTACGCGGGCTACCATATCCCCAAGGGGTGGAAGTTGTAT
TGGAGCTCGTCCAACACACATAGGGACCCAAGCTTGTTCACGAGCTACACCAGGTTT
GATCCATCGAGATTTGAAGAGTCACCGGGGCCAGCCCCATTTTCGTATGTGCCGTTT
GGTGGGGGGCCTAGGATGTGCCTGGGGAAAGAGTTTGCAAGGCTGGAGATACTCAT
ATTTTTACACAACGTGATTAAAAGATATAGGTGGAAGTTGGTGAATCCTGATGAGAA
AATTGCATATGATCCAATGCCCACACCTGTGGAAGGACTTCCCATTCTTATCCAACCA
CAGACATAG  
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The sequence of RoCYP03 
ATGGAGCTCCTAACGTTAGCTGTTTCCTTACTCCTCATCGCCCTCACATTCTTC
CTCCTCCGCCGTAGCTCCGGCGGCGTCGATGCCCTCCCCCCGGGCAGCTTCGG
GTGGCCGTTGCTGGGAGAGAGCGTCGAGTTCCTGTTCGGCAAGCCGGAGAAA
TTCGTCGGCGACCGGATGAAGAAATACTCGCTGGACATCTTCAAAACTAAAA
TCCTCGGTGAGAAAACCGCCGTGATCTGCGGCCCCGCCGGCCACAAATTCCT
CTTCTCCAACGAGCAGAAGTACTTCACCGCATTCCGCCCCCACCCCATGCAGC
ACCTCTTCCGCTCCTACAAACCTAAATCCGCCTCCGCCGCCGAGAAGCCGGCT
GAAGCCGCCGCTCCGCCGACGACCAAAGCCACCGACGAGACCAAGGCCATA
CGCCAGCCCGGATTCCTCAAGCCCGAAGCCCTAATGCGATTTTTGGCGGGGA
TGGATTTAATCACTCAAAAGCAGCTGCAAATTCACTGTGCAGGTAAAAACGT
GGTCCAGTTTTACCCGCTGTCGAAAACAATTACCCTAACCATCGCGTGCCAGT
TTTTTATGGGTATTAATAACCCGGAGCGCATCGCGCGCTTGGTGAAAAACTTC
GACGATGTTACCGTGGGGATGCACTGCATCATGTTAAACTTACCGGGCACGA
TTTTTTACCGCGGTAACAAAGCTGCGGCGGCGCTCAGGAAGGAACTGATCGC
TGTCATCAAGGAGAAGAAGCAATCTATCGCCGGCGGGGCGCCGCTGCACGAC
ATCTTGTCGCACATGATCGTCGCCTCTGACCCGGCAGGGAGATCCATGCCCG
AACCTGAGATCGCAGATAAGATTATGGGGATTTTGACCGCCGGGTATAGTAC
GGTGGCGACCACGATGACCTTCTTGATGAAGTATCTAGGGTTGAATCCCGAT
ATCTACGAACGAGTTCGTGCAGAGCAATTGGAGATTGCGGCTGTGAAGAAAG
AAGGGGAACCATTGAATTGGGAAGATATGGGGAAAATGAAGTATTCATGGA
ATGTGATATGCGAGACAATGAGAATGGTTCCTCCATTGCAAGGGACATTTAG
GGAAGTGCTCGAGGAATTTACATATGCCGGCTACAATATTCCCAAGGGCTGG
AAGGTATATTGGACGGTGAGCACAACCAACATGAACCCACAGTATTTCAAG 
AATCCAGAGAGATTCAATCCATCGAGATATGAGGAGGGAGAAGCGCCTCCGC
CGTACACCTACGTTCCATTCGGGGGAGGGCCGAGAATGTGCCCCGGAAAAGA
GTACGCTAGAATATCAATATTGGCTTTCGTTCACAATGTTGTGAAGAATTACC
GGTGGGAAGTTGTCGATCCAAATGAGAAGGTGGAAGGAGATATGATGCCGG
AGCCGCAGAAAGGTCTGCCGGTCCGCCTTTACAAACAGTGA  
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The truncated sequence of BpCYP01 
……AAAACCGGGTACCCCATGATCGGCGAGAGCCTTGAGTTCTTGTCCACCGGATGG
AAAGGCCATCCGGAAAAGTTCATCTTCGACCGCATGACCAAGTTCTCATCGGAAGTC
TTCAAAACCTCCCTTCTTGGGCAGCCGGCCGCCGTCTTCTGTGGCGCGGCGTGTAACA
AGTTCTTGTTTTCCAATGAGAACAAGCTTGTAACTGCCTGGTGGCCGGACTCCGTCAA
C……ATCATAAAGCAGCGAAGGGTTGATTTGGGTGAGGGCAAGGCAAGCCCTACAC
AAGACATACTCTCTCACATGCTCTTGACTTCCGACGAGAGTGGGCAGTACATGACTG
AATTAGATATTGCCGACAAAATCCTCGGCCTGCTCATCGGCGGCCACGACACCGCCA
GCGCTGCTTGCACTTTCATTGTCAAGTATCTTGCTGAGCTTCCTCATATTTATGAGGG
TGTCTACAATGAGCAAATGGAGATAGCCAATTCCAAAGCACCCGGGGAGTTATTGAA
CTGGGAGGATATTCAAAAGATGAGGTATTCATGGAACGTAGCTTGTGAAGTCTTGAG
GCTTGCTCCACCGCTCCAAGGAGCTTTCCGGGAAGCCATTAATGACTTCATCTTCAAT
GGTTTCTCCATTCCCAAGGGCTGGAAGTTGTACTGGAGTGCAAACTCGACACACAGG
AGTGCGGAATACTTCCCAGAACCTGAGAAATTTGATCCGAGTAGATTTGAAGGAAGG
GGACCGGCACCGTACACATTTGTTCCATTTGGTGGAGGGCCGAGGATGTGCCCGGGA
AAAGAATATGCCCGATTGGAAATACTTGTTTTCATGCACAACTTAGTGAAAAGGTTC
AGGTGGGAGAAGATGATTCCTGATGAGAAAATCGTAGTTGATCCCATGCCCATGCCT
GCAAAGGGCCTGCCCGTTCGCCTTTACCCTCAC……  
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The sequence of RoCPR01 
ATGGAACCCTCGTCGCCGAAGCTCTCGCCGCTCGATTTCATAGCGGCGATCTTAAAG
GGCGATATTGAGGGGGCGGCGCCGCGGGGTGTGGCGGCGATGTTGATGGAGAACAG
AGACCTCGCGATGGTGCTCACTACATCCGTCGCGTTGCTCATAGGCTGCGTCGTTGTG
CTAGCGTGGCGGCGCACCGCCGGATCGGCGGGGAAGAAGCAGCTACAGCCGCCCAA
GCTGGTGGTGCCGAAGGCGGCGGTGGAGCCGGAGGAGGCGGAGGATGACAACACCA
AGGTTTCCGTCTTCTTCGGCACACAGACTGGTACAGCTGAAGGTTTCGCAAAGGCAT
TTGCTGAGGAAGCTAAAGCTAGATATCCACAGGCCAAGTTTAAAGTAATTGACTTAG
ATGATTATGCTGCCGATGATGATGAGTACGAGGATAAGTTGAAGAAGGAGAGTTTA
GCATTCTTCTTCCTGGCCTCATATGGAGATGGTGAGCCTACAGACAATGCTGCAAGG
TTCTACAAATGGTTTACTGAGGGAAAAGATAGGGAGGAATGGCTTAAGAATCTTCAG
TACGCTATATTCGGTCTTGGGAACAGACAATACGAGCATTTCAACAAGATTGCGATA
GTGGTAGATGACCTTATCACCGAGCAAGGAGGAAAGAAGCTTGTTCCAGTAGGCTTG
GGAGATGATGACCAATGCATTGAAGATGACTTTACTGCATGGCGTGAATTATTGTGG
CCTGAGTTGGATAAATTGCTCCGCAACGAGGACGATGCAACGGTTGCTACTCCATAC
ACTGCTGCGGTGTTGCAGTATCGTGTTGTGCTCCATGACCAAACAGATGGATTGATT
ACAGAGAATGGTTCACCAAATGGTCGTGCCAATGGTAACACTGTATATGATGCTCAA
CATCCCTGCAGGGCAAATGTTTCTGTAAAGAGAGAGCTGCACACTCCTGAATCAGAT
CGTTCTTGCACTCATTTGGAATTTGACATAGCTGGCACAGGACTTGTGTATGAAACG
GGGGACCATGTTGGTGTCTATTGTGAGAATTTGCTCAAGAATGTGGAGGAAGCGGAA
AAGTTACTAAATCTGTCCCCGCAAACATACTTTTCAGTTCATACTGATAACGAGGAT
GGCACTCCACTCAGTGGAAGCTCTTTGCCACCTCCATTCCCCCCTTGCACTTTGCGGA
CAGCACTAACTAAATACGCAGATCTTATGAGTATGCCCAAAAAGTCTGTGCTAGTTG
CATTAGCGGAATATGCTTCTGACCAAAGTGAAGCTGATCGACTCAGATATCTTGCAT
CCCCCGATGGAAAGGAGGAATATGCACAGTATGTAGTTGCAAGTCAGAGAAGCCTA
CTGGAGATCATGGCCGAGTTCCCGTCCGCCAAGCCTTCTCTAGGTGTTTTCTTTGCAG
CTGTTGCTCCTCGGCTCCAGCCCAGATTTTATTCTATCTCATCCTCCCCGAAAATCGC
ACCAACCAGAGTTCATGTGACTTGTGCTCTGGTTTATGACAAAACACCAACAGGACG
AATCCACAAGGGTATATGCTCTACATGGATAAAGAATGCTGTGCCTTTGGAGGAAAG
TAGCGATTGCAGTTGGGCACCAATTTTTATTAGAAGCTCTAACTTCAAACTCCCTACT
GATCCTAAAGTACCGGTAATAATGGTCGGCCCTGGTACTGGCTTGGCTCCATTTAGG
GGTTTCCTTCAGGAAAGGTTAGCTCTAAAGGAATCTGGAGCTGAACTTGGTCCTGCC
ATTTTATTTTTTGGTTGTAGGAACCGTAAAATGGATTTTATTTATGAAGATGAGTTGA
ATGGCTTTGTCAAAGCTGGAGCAATTTCCGAGCTCATAGTTGCTTTCTCACGTGAGGG
ACCTGCGAAGGAATACGTGCAACACAAGATGTCTCAAAGGGCTTCGGACGTCTGGA
AAATGATCTCCGATGGAGGTTATGTCTACGTCTGTGGTGATGCCAAGGGAATGGCGC
 
 
22 
 
GTGATGTACACCGAACTCTCCACACAATCGCACAAAAACAGGGTTGTCTGAGCAGCT
CCGAAGCCGAAGGCATGGTCAAGAATCTGCAAACGACAGGAAGATATTTGCGCGAT
GTATGGTGA  
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The sequence of OptiRoCYP01 
ATGGAATTTTTCTATGCATCTTTGTTGTGTTTGTTTGTTTCTTTAGTTTTCTTGTCATTG
CATTTGTTATTTTACAAGACTAAGACAGGTTCATTGCCTCCAGGTAAAACTGGTTGGC
CAGTTATTGGTGAATCTTTGGAATTTTTATCAACAGGTTGGAAGGGTCATCCAGAAA
AGTTTATTTTCGATAGAATGGCTAGATATTCTTCACATGTTTTTAGAACTCATTTGTTA
GGTGAACCAGCTGCAGTTTTATGTGGTTCTGCTGGTAATAAGTTCTTGTTTTCAAACG
AAAATAAGTTAGTTCAAGCATGGTGGCCATCTTCAGTTGAAAAGATTTTCCCAAACG
ATAACGCTGAAACTTCTTCAAAGGAAGAATCTATTAAAATGAGAAGAATGTTGCCAA
CTTTCTTTAAGCCAGAAGCATTGCATAGATACGTTGGTATCATGGATCATATCGCTAG
AAGACATTTTGCAGATGGTTGGGATGGTAAAAGAGAAGTTGTTGTTTTCCCATTGGC
TAAAAATTACACTTTCTGGTTGGCATGTAGATTGTTTTTATCTGTTGAAGATCCATCA
CAAGTTGAAAAGTTCGCTGCACCTTTTAATTTGTTGGCTTCTGGTTTGATCTCAATCC
CAATCGATTTGCCAGGTACACCATTCCATAAGGGTATTAAAGCTTCTGCATACATCA
GAAAGGAATTGGTTGCTATTATTAAGCAAAGAAAGGCTGATTTGGCAGATGGTACTG
CATCTCCAACACAAGATATCTTGTCTCACATGTTGTTGACATCAAACGAAGATGGTA
AATTCATGCAAGAATCAGATATCGCTAATAAGATCTTGGGTTTGTTGATTGGTGGTC
ATGATACTGCTTCTTCAGCATGTACATTCGTTGTTAAGTATTTGGCAGAATTGCCACA
AGTTTACGAAGGTGTTTACAAGGAACAAATGGAAATCGCTAAGTCTAAAGCTGCTGG
TGAATTGTTGAACTGGGAAGATTTGCAAAAGATGAAGTACTCATGGAATGTTGCATG
TGAAGTTTTGAGATTAGCTCCACCATTGCAAGGTGCTTTTAGAGAAGCTTTGGCAGA
TTTCTCTTTTAATGGTTTTTCAATCCCAAAGGGTTGGAAGTTGTACTGGTCTGCTAATT
CAACTCATAAAAATTCTGAATTTTTCCCAGAACCAGAAAAGTTCGATCCATCTAGAT
TCGAAGGTTCAGGTCCAGCACCATATACATTTGTTCCATTTGGTGGTGGTCCAAGAAT
GTGTCCTGGTAAAGAATACGCTAGATTGGAAATCTTGGTTTTTATGCATCATTTGGTT
AAGAGATTCAAATGGGAAAAGATGATCCCAGATGAAAAGATTGTTGTTGATCCAAT
GCCAATTCCAGCTAATGGTTTGCCAGTTAGATTATACCCACATACTTCTTAA  
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The sequence of OptiAtLUP 
ATGTGGAAGTTGAAGATAGGTGAAGGTGGTGCTGGTTTGATTTCTGTAAACA
ATTTTATAGGTAGACAACACTGGGAATTTGACCCTAACGCTGGTACCCCTCAA
GAACATGCAGAAATCGAAAGATTGAGAAGAGAATTCACTAAAAATAGATTCT
CCATCAAGCAAAGTGCTGATTTGTTGATGAGAATGCAATTGAGAAAGGAAAA
CCACTACGGTACAAACAACAACATCCCAGCTGCAGTTAAATTGTCTGACGCC
GAAAATATAACCGTTGAAGCATTGGTCACTACAATAAGAAGAGCTATATCTT
TTTACTCTTCAATTCAAGCACATGATGGTCACTGGCCAGCAGAATCAGCCGGT
CCTTTATTTTTCTTGCAACCATTAGTTATGGCTTTATACATCACCGGTTCCTTG
GATGACGTCTTAGGTCCAGAACATAAAAAGGAAATCGTAAGATATTTGTACA
ACCACCAAAATGAAGATGGTGGTTGGGGTTTTCATATAGAAGGTCACTCTAC
TATGTTCGGTTCTGCATTATCATATGTCGCCTTGAGAATCTTAGGTGAAGGTC
CTGAAGATAAAGCTATGGCAAAAGGTAGAAAGTGGATCTTAGACCATGGTGG
TTTGGTTGCAATTCCATCCTGGGGTAAATTTTGGGTTACTGTCTTAGGTGCTTA
TGAATGGAGTGGTTGTAATCCTTTGCCACCTGAATTATGGTTGTTACCAAAGT
TTACTCCATTCCATCCTGGTAAAATGTTGTGTTACTGCAGATTGGTATACATG
CCTATGTCCTATTTGTACGGTAAAAAGTTCGTTGGTCCAATCACTGCTTTGAT
CAGAAGTTTAAGAGAAGAATTATACAACGAACCTTACAACCAAATTAACTGG
AATACAGCTAGAAACACCGTTGCAAAAGAAGATTTGTATTACCCACATCCTT
TGATACAAGACATGTTATGGGGTTTCTTGTATCACGTCGGTGAAAGATTTTTA
AACTGTTGGCCATTCTCTATGTTAAGAAGAAAAGCCTTGGAAATTGCTATAA
ACCATGTACACTACGAAGATGAAAATTCCAGATACTTGTGTATAGGTAGTGT
CGAAAAGGTATTATGCTTGATCGCAAGATGGGTTGAAGACCCTAATTCAGAA
GCATATAAATTGCATTTGGCCAGAATCCCAGATTACTTTTGGTTAGCTGAAGA
CGGTTTGAAGATTCAATCCTTTGGTTGTCAAATGTGGGATGCCGCTTTCGCTA
TCCAAGCAATTTTAGCCTGCAATGTTAGTGAAGAATATGGTCCTACATTGAGA
AAAGCTCATCACTTTGTAAAGGCATCTCAAGTTAGAGAAAACCCATCTGGTG
ACTTCAATGCCATGTACAGACATATTTCCAAAGGTGCTTGGACTTTTAGTATG
CATGATCACGGTTGGCAAGTCTCAGACTGTACAGCAGAAGGTTTAAAGGCAG
CCTTGTTATTGTCTGAAATGCCTTCAGAATTAGTAGGTGGTAAAATGGAAACT
GAAAGATTCTACGATGCTGTAAACGTTATCTTATCTTTGCAATCCAGTAATGG
TGGTTTCCCAGCCTGGGAACCTCAAAAAGCATATAGATGGTTGGAAAAGTTT
AATCCAACTGAATTTTTCGAAGATACAATGATCGAAAGAGAATACGTTGAA 
TGTACAGGTTCTGCCATGCAAGGTTTAGCTTTGTTTAGAAAACAATACCCTCA
ACATAGATCAAAGGAAATAGATAGATGCATCGCCAAGGCTATCAGATACATC
GAAAACATGCAAAATCCAGACGGTTCTTGGTACGGTTGTTGGGGTATTTGCT
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ATACCTACGGTACTTGGTTCGCAGTTGAAGGTTTGACAGCCTGTGGTAAAAA
CTGCCATAATTCCTTAAGTTTGAGAAAGGCATGTCAATTCTTGTTGTCTAAGC
AATTGCCAAATGCTGGTTGGGGTGAATCATATTTGTCTTCACAAAACAAGGTT
TACACCAATTTGGAGGGTAACAGAGCAAATTTGGTCCAATCCAGTTGGGCCT
TATTGTCTTTAACACATGCTGGTCAAGCAGAAATTGATCCAACCCCTATCCAC
CGTGGTATGAAATTGTTGATTAACTCACAAATGGAAGATGGTGACTTTCCAC
AACAAGAAATAACCGGTGTTTTCATGAGAAACTGCACTTTGAACTACTCTTCA
TACAGAAATATTTTTCCAATATGGGCAATGGGTGAATACAGAAGACAAGTTT
TATGTGCTCACTCCTACTAA 
